Okay, I only evaluate management based on how successfully they can make the turnaround and I guess you cannot say that yet... The current management has connections to big Pharmas and those connections may come handy. It is not easy to get development partners nowadays without connections. Yes that cashless warrant deal was bad for longs in the short-term, but then again it is not easy to get funding is you are tiny Pharma without any FDA approved products on the market. Also if you are thinking short-term movements, you are not real long...you mighs as well be short..
AEZS is bankruptcy priced at the moment. Actually if AEZS would go bankrupt it would probably trade higher than now solely based on CPS and patents/Pipe. Probably between 0.15-0.35 cetns.
News 
Market Data 
Discover 
